Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 12/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 12/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1576962 | 0.83 | CRHBP (0.38) | LMNA | |
| SCHEMBL20264517 | 0.77 | HSD17B2 (0.61) | MTNR1AMTNR1BHSD17B2HSD17B1CES2 | |
| SCHEMBL4073070 | 0.76 | G6PC1 (0.56) | — | |
| SCHEMBL1012749 | 0.76 | MTNR1A (0.51) | MTNR1AMTNR1BHSD17B2HSD17B1CES2 | |
| SCHEMBL1703740 | 0.76 | MTNR1A (0.50) | MTNR1AMTNR1BHSD17B2HSD17B1CES2 | |
| SCHEMBL4293536 | 0.76 | MTNR1A (0.50) | MTNR1AMTNR1BHSD17B2HSD17B1CES2 | |
| SCHEMBL27839545 | 0.76 | MTNR1A (0.50) | MTNR1AMTNR1BHSD17B2HSD17B1CES2 | |
| SCHEMBL17501940 | 0.73 | MTNR1A (0.49) | MTNR1AMTNR1BHSD17B2HSD17B1CES2 | |
| SCHEMBL26624252 | 0.71 | MTNR1B (0.56) | MTNR1AMTNR1BHSD17B2HSD17B1CES2 | |
| SCHEMBL1576942 | 0.71 | NPSR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335908-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | LILLY CO ELI (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7304062-B2 | Peroxisome proliferator activated receptor alpha agonists | ELI LILLY AND COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-20040102500-A1 | Peroxisome proliferator activated receptor alpha agonists | CANO IVAN COLLADO (ES) | 2004-05-27 | — | — | US | disclosed |
| EP-1335908-A2 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | ELI LILLY AND COMPANY (US) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002038553-A2 | TRIAZOLE DERIVATIVES AND THEIR USE AS PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | ELI LILLY AND COMPANY (US) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102500-A1 | Peroxisome proliferator activated receptor alpha agonists | PPARG, PPARA, PPARD | MTNR1A 400/4885MTNR1B 853/4885HSD17B2 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.